Formycon AG

Update in progress

FYB.DE (XETRA)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Formycon AG is a Planegg, Germany-based biotechnology company that develops biosimilar medicines for Germany and Switzerland. It markets ranibizumab and aflibercept for neovascular age-related macular degeneration, diabetic macular edema, and related ocular conditions under various brand names. Its pipeline includes ustekinumab for Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, plus pembrolizumab and FYB208/FYB209 for immunology and oncology. Formerly Nanohale AG, renamed in 2012; founded in 1999.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive